Ajanta Pharma Limited has released its Annual Secretarial Compliance Report for the fiscal year ended 31st March 2026. The report, prepared by independent practitioners, confirms the company’s adherence to corporate governance standards and regulatory requirements. This transparency initiative highlights the company’s commitment to maintaining robust internal controls and ethical business practices throughout the 2025-2026 financial period, ensuring long-term value for all stakeholders.
Commitment to Corporate Governance
The Annual Secretarial Compliance Report serves as a comprehensive validation of Ajanta Pharma’s operational transparency. During the 2025-2026 financial year, the company demonstrated strict compliance with key governance frameworks, including secretarial standards, maintenance of functional websites, and the timely disclosure of material information. This review process provides shareholders and investors with assurance regarding the company’s management integrity and adherence to statutory mandates.
Review Findings and Transparency
The audit process, conducted by M/s. D.G. Prajapati & Associates, encompassed a wide range of administrative and legal protocols. The evaluation confirmed that the company effectively managed its board processes, maintained accurate statutory registers, and fulfilled its obligations regarding insider trading protocols and related party transactions. The report notes that all policies were reviewed and updated to reflect current requirements, ensuring that the company remains aligned with best-in-class corporate practices.
Focus on Operational Excellence
As part of its ongoing governance framework, Ajanta Pharma continues to prioritize the preservation of documents and the timely dissemination of information. The successful conclusion of this compliance review reinforces the company’s dedication to robust oversight, shielding it from potential regulatory risks. By consistently meeting these high standards, Ajanta Pharma strengthens its position as a reliable and transparent leader in the pharmaceutical sector, dedicated to maintaining the trust of its investors and the broader market.
Source: BSE
